174 results
8-K
EX-99.1
AORT
Artivion Inc
1 Apr 20
Results of Operations and Financial Condition
4:30pm
initiatives in response to the potential impact of COVID-19 on its operations. These are:
Health and Safety: To reduce the risk to CryoLife’s employees … personal travel, to protect the health and safety of its employees, patients and customers.
Continuing to manufacture and support patients: Currently
8-K
EX-99.1
AORT
Artivion Inc
23 Sep 22
Regulation FD Disclosure
4:14pm
on apixaban rather than on warfarin. The decision was based on the recommendation of the independent Data and Safety Monitoring Board (DSMB) of the trial … would yield equivalent safety to the standard anticoagulant, warfarin. Unfortunately, it appears that it does not. On behalf of all of the investigators
DEFA14A
AORT
Artivion Inc
7 May 02
Additional proxy soliciting materials
12:00am
publicity that may have caused concern among
shareholders, tissue donors and recipients about the safety of preserved human
tissue, CryoLife … .
CryoLife continues its ongoing commitment to tissue safety by expanding its
long-standing quality assurance programs, educational efforts
8-K
EX-99.1
AORT
Artivion Inc
2 Sep 20
Entry into a Material Definitive Agreement
4:16pm
. It is likely to become the standard of care because of its ease of adoption, simplicity, safety, and effectiveness, particularly with the sickest patients … , possibly improve survival; and is likely to become the standard of care due to its ease of adoption, simplicity, safety, and effectiveness
8-K
EX-10
8he42z1 1t1w
5 Aug 05
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
qgtofubypekt4wp2m51
21 Aug 03
Other events
12:00am
8-K
EX-99.1
41kx57c3
2 Nov 23
Artivion Reports Third Quarter 2023 Financial Results
4:10pm
8-K
1mff9yil 45jpqqs6wo
23 Sep 22
Regulation FD Disclosure
4:14pm
8-K
EX-99.1
je2uxx9kfkuum
12 Feb 08
CryoLife Receives FDA 510(k) Clearance for SynerGraft® Processed Human Pulmonary Heart Valves
12:00am
424B3
sm0qn8zd
16 Jan 97
Prospectus supplement
12:00am
424B3
99rmq4c4z bu
18 May 04
Prospectus supplement
12:00am